FY2027 Earnings Estimate for IRWD Issued By Zacks Research

Key Points

• Zacks Research has revised its FY2027 EPS estimate for Ironwood Pharmaceuticals to (-$0.03), a decrease from a previous estimate of (-$0.02), while the consensus for current full-year earnings is $0.10 per share.
• Ironwood's stock rating has seen mixed reviews, with Wall Street Zen upgrading it to a "buy" and Craig Hallum downgrading it to a "hold."
• Despite recent downgrades, Ironwood Pharmaceuticals reported a quarterly EPS of $0.14, surpassing estimates and achieving revenues of $85.24 million against an expected $62.02 million.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Stock analysts at Zacks Research decreased their FY2027 EPS estimates for shares of Ironwood Pharmaceuticals in a research report issued to clients and investors on Tuesday, August 5th. Zacks Research analyst R. Department now expects that the biotechnology company will post earnings of ($0.03) per share for the year, down from their previous forecast of ($0.02). The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.10 per share.

Several other research analysts have also commented on the stock. Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Craig Hallum downgraded shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 16th. Leerink Partners lowered their price target on shares of Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating on the stock in a report on Monday, April 14th. Citizens Jmp downgraded shares of Ironwood Pharmaceuticals from an "outperform" rating to a "market perform" rating in a report on Monday, April 14th. Finally, Wells Fargo & Company restated an "equal weight" rating and set a $1.00 price objective (down from $7.00) on shares of Ironwood Pharmaceuticals in a research report on Tuesday, April 15th. Seven research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, Ironwood Pharmaceuticals presently has a consensus rating of "Hold" and a consensus target price of $4.78.

Ironwood Pharmaceuticals Price Performance

Shares of NASDAQ:IRWD traded down $0.03 during trading hours on Friday, hitting $0.85. The company's stock had a trading volume of 386,697 shares, compared to its average volume of 2,925,522. The company has a market capitalization of $138.19 million, a price-to-earnings ratio of -4.27 and a beta of 0.33. The firm's fifty day moving average price is $0.73 and its 200 day moving average price is $1.20. Ironwood Pharmaceuticals has a 52 week low of $0.53 and a 52 week high of $5.21.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biotechnology company reported $0.14 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.16. Ironwood Pharmaceuticals had a negative net margin of 9.89% and a negative return on equity of 1.87%. The business had revenue of $85.24 million during the quarter, compared to analyst estimates of $62.02 million.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Armistice Capital LLC increased its position in Ironwood Pharmaceuticals by 44.7% during the first quarter. Armistice Capital LLC now owns 13,700,000 shares of the biotechnology company's stock worth $20,139,000 after purchasing an additional 4,232,000 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Ironwood Pharmaceuticals by 186.6% in the first quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company's stock valued at $9,349,000 after purchasing an additional 4,140,439 shares during the period. Acadian Asset Management LLC lifted its stake in Ironwood Pharmaceuticals by 147.6% in the second quarter. Acadian Asset Management LLC now owns 6,549,687 shares of the biotechnology company's stock worth $4,685,000 after acquiring an additional 3,904,498 shares during the last quarter. Jane Street Group LLC lifted its stake in Ironwood Pharmaceuticals by 740.5% in the first quarter. Jane Street Group LLC now owns 3,510,117 shares of the biotechnology company's stock worth $5,160,000 after acquiring an additional 3,092,475 shares during the last quarter. Finally, AQR Capital Management LLC lifted its stake in Ironwood Pharmaceuticals by 535.8% in the first quarter. AQR Capital Management LLC now owns 2,523,875 shares of the biotechnology company's stock worth $3,710,000 after acquiring an additional 2,126,889 shares during the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.